We show that the TLR8 pathway is a potential therapeutic target during Mtb infection since it is sub-maximally activated physiologically and, when stimulated pharmacologically by resiquimod, enhances clearance of drug-susceptible and MDR-TB in vitro and in vivo. This evidence concerns the gene TLR8 and tuberculosis.